Literature DB >> 18188510

Antithrombin after cardiac surgery: implications on short and mid-term outcome.

Domenico Paparella1, Giangiuseppe Cappabianca, Giuseppe Scrascia, Giuseppe Fiore, Andreas Paramythiotis, Nicola Di Bari, Maria Pia Trisorio Liuzzi, Mohamed F Ibrahim, Tommaso Fiore, Luigi de Luca Tupputi Schinosa.   

Abstract

BACKGROUND: Antithrombin (AT) drop during cardiac surgery has been described. The causes and the effects of this phenomenon are not clear. The objective of the study is to evaluate the relationship of AT postoperative values on short and mid-term outcome after cardiac surgery.
METHODS: Between January and June 2005, 405 patients, who underwent cardiac operations at our Institution had AT values available preoperatively and postoperatively. Using Receiver Operating Characteristic curves, a cut-off equal to 63.7% for ICU-arrival AT was chosen in order to divide the entire population in two groups (117 patients with ICU-arrival AT < 63.7%, Low AT group, and 288 patients with ICU-arrival AT > or = 63.7%, High AT group). Objective of the study was to evaluate the predictive role of ICU-arrival AT < 63.7% on in-hospital mortality and morbidity and on 18 months follow-up after cardiac surgery.
RESULTS: ICU-arrival AT was significantly lower than preoperative AT (90.7 +/- 16.3% vs. 71.2 +/- 15.1%, P < 0.0001). Patients in the Low AT group were older, more often female, had a worse Euroscore and required longer CPB duration and cross clamp time. They had significantly higher preoperative and postoperative D-dimer levels. ICU arrival AT < 63.7% was not associated with increased in-hospital mortality but it was an independent risk factor for longer mechanical ventilation, need of inotropic support, excessive bleeding and blood products transfusion. ICU arrival-AT < 63.7% was associated with worse survival during 18 months follow up (92.3% vs. 85.4% in the High AT and Low AT group, respectively, P = 0.05).
CONCLUSIONS: Low AT after cardiac surgery is associated with higher incidences of peri-operative complications and worse survival in the mid-term. Future studies should clarify the pathophysiologic mechanism of this findings and possible therapeutic directions.

Entities:  

Mesh:

Year:  2008        PMID: 18188510     DOI: 10.1007/s11239-007-0191-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  22 in total

1.  Activation of the coagulation system during coronary artery bypass grafting: comparison between on-pump and off-pump techniques.

Authors:  Domenico Paparella; Antonella Galeone; Maria Teresa Venneri; Maria Coviello; Giuseppe Scrascia; Nicola Marraudino; Michele Quaranta; Luigi de Luca Tupputi Schinosa; Stephanie J Brister
Journal:  J Thorac Cardiovasc Surg       Date:  2006-02       Impact factor: 5.209

2.  Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery.

Authors:  John H Lemmer; George J Despotis
Journal:  J Thorac Cardiovasc Surg       Date:  2002-02       Impact factor: 5.209

3.  Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

Authors:  F Baudo; T M Caimi; F de Cataldo; A Ravizza; S Arlati; G Casella; D Carugo; G Palareti; C Legnani; L Ridolfi; R Rossi; A D'Angelo; L Crippa; D Giudici; G Gallioli; A Wolfler; G Calori
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

4.  The role of antithrombin III in the perioperative management of the patient with unstable angina.

Authors:  M Rossi; L Martinelli; S Storti; M Corrado; R Marra; C Varano; R Schiavello
Journal:  Ann Thorac Surg       Date:  1999-12       Impact factor: 4.330

5.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

6.  Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits.

Authors:  Gabriel S Aldea; Louise O Soltow; Wayne L Chandler; Christopher M Triggs; Craig R Vocelka; Gregory I Crockett; Yong T Shin; William E Curtis; Edward D Verrier
Journal:  J Thorac Cardiovasc Surg       Date:  2002-04       Impact factor: 5.209

7.  Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass.

Authors:  S Zahler; P Massoudy; H Hartl; C Hähnel; H Meisner; B F Becker
Journal:  Cardiovasc Res       Date:  1999-03       Impact factor: 10.787

8.  Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation.

Authors:  T F Slaughter; J B Mark; H El-Moalem; K A Hayward; A K Hilton; L P Hodgins; C S Greenberg
Journal:  Blood Coagul Fibrinolysis       Date:  2001-01       Impact factor: 1.276

9.  Postoperative antithrombin levels and outcome in cardiac operations.

Authors:  Marco Ranucci; Alessandro Frigiola; Lorenzo Menicanti; Antonio Ditta; Alessandra Boncilli; Simonetta Brozzi
Journal:  Crit Care Med       Date:  2005-02       Impact factor: 7.598

Review 10.  Antithrombin: a new look at the actions of a serine protease inhibitor.

Authors:  J Roemisch; E Gray; J N Hoffmann; C J Wiedermann
Journal:  Blood Coagul Fibrinolysis       Date:  2002-12       Impact factor: 1.276

View more
  4 in total

1.  Strategy for Cardiovascular Surgery in Patients with Antithrombin III Deficiency.

Authors:  Yoshiyuki Nishimura; Yasushi Takagi
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-04-20       Impact factor: 1.520

2.  Dexamethasone Preconditioning in Cardiac Procedures Reduces Decreased Antithrombin Activity and Is Associated to Beneficial Outcomes: Role of Endothelium.

Authors:  Vicente Muedra; Lucrecia Moreno; Vicente Rodilla; Cristina Arce; Fermi Montó; Águeda Blázquez; Paloma Pérez; Pilar D'Ocón
Journal:  Front Pharmacol       Date:  2018-09-25       Impact factor: 5.810

3.  A Prospective Observational Study on Multiplate®-, ROTEM®- and Thrombin Generation Examinations Before and Early After Implantation of a Left Ventricular Assist Device (LVAD).

Authors:  Philipp Opfermann; Alessia Felli; Christine Schlömmer; Martin Dworschak; Michele Bevilacqua; Mohamed Mouhieddine; Daniel Zimpfer; Andreas Zuckermann; Barbara Steinlechner
Journal:  Front Med (Lausanne)       Date:  2022-02-25

Review 4.  Biomarkers in Coronary Artery Bypass Surgery: Ready for Prime Time and Outcome Prediction?

Authors:  Alessandro Parolari; Paolo Poggio; Veronika Myasoedova; Paola Songia; Giorgia Bonalumi; Alberto Pilozzi; Davide Pacini; Francesco Alamanni; Elena Tremoli
Journal:  Front Cardiovasc Med       Date:  2016-01-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.